Skip to content

Mindfulness Training Hidradenitis Suppurativa (HS)

Effectiveness of Mindfulness Training on the Quality of Life of Hidradenitis Suppurativa Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05642039
Enrollment
37
Registered
2022-12-08
Start date
2023-05-01
Completion date
2025-08-21
Last updated
2025-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hidradenitis Suppurativa, Quality of Life

Brief summary

The purpose of this research is to investigate the effectiveness of mindfulness training on the quality of life of Hidradenitis Suppurativa (HS) patients. HS can have a profound impact on quality of life.

Interventions

Participants will attend a weekly 1.5-hour class over a 6-week period via Zoom. Participants will also be required to listen to guided practice audio recordings that are 12-20 minutes long and complete a weekly homework log detailing all audio recordings completed.

BEHAVIORALHS Educational Course

Participants will meet for 10 -15 minutes once a week over a 6-week period. The course will be administered verbally or with the use of PowerPoint slides.

Sponsors

University of Miami
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Hidradenitis Suppurativa patients registered in the University of Miami Hospital dermatology system. Patients can have lesions present at the time of study participation

Exclusion criteria

* Individuals with any of the following: active drug addictions, untreated Post Traumatic Stress Disorder (PTSD), psychosis or suicidal ideations * Adults unable to consent * Pregnant women * Prisoners * Individuals below the age of 18 years old * Individuals who do not speak English

Design outcomes

Primary

MeasureTime frameDescription
HS Quality of Life Measure (HiSQOL) ScoresUp to 10 weeksHS quality of life (HiSQOL) has a total score ranging from 0 to 68, with higher scores indicating more severe impact on participant's quality of life

Secondary

MeasureTime frameDescription
Number of participants at each Refined Hurley ClassificationUp to 10 weeksThe Hurley Classification is staged as: 1 (single or multiple abscesses without sinus tract formation or scarring); 2 (recurrent abscesses with one or more sinus tracts and scarring widely separated by normal skin); 3 (diffuse involvement with multiple sinus tracts and no intervening normal skin).
Hidradenitis Suppurativa Physician's Global Assessment Scale (HS-PGA) ScoresUp to 10 weeksHS Physician's Global Assessment (HS-PGA) Scale is a 6-point Likert scale from 0 (clear) to 5 (very severe). Total score ranges from 0 to 30 with the higher score indicating more severe HS symptoms
Five-Facet Mindfulness Questionnaire - Short Form (FFMQ-SF) ScoresUp to 10 weeksFFMQ-SF has total scores ranging from 15 to 75. Higher scores indicate greater levels of mindfulness.
Pain Visual Analog Scale (VAS) ScoresUp to 10 weeksPain VAS has a range from 0 to 10 with a higher score indicating worse pain
Dermatology Life Quality Index (DLQI) ScoresUp to 10 weeksDermatology Life Quality Index (DLQI) has a total score ranging from 0 to 30 with the lower score indicating higher health related quality of life
Number of Pain medication UsageUp to 10 weeksPatient reported number of pain medications used by participants in the past week
Number of work/school days missedUp to 10 weeksPatient reported number of work/school days missed in the past week
Number of visits to the emergency roomUp to 10 weeksPatient reported number of visits to the emergency room in the past week
Sleep Quality Scale (SQS) ScoresUp to 10 weeksSleep Quality Scale (SQS) has a score ranging from 0-10 with a greater score indicating greater sleep quality

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026